

# Monday 17th June

|               |  |   |   |   |
|---------------|--|---|---|---|
| 8:00 - 9:00   | <b>Registration</b><br><b>(Pre-Conference session: Introduction for students and new starters)</b>   |   |   |   |
| 9:00 – 9:30   | <b>Conference Opening Remarks</b>  |   |   |   |
| 9:30 – 10:30  | <b>Geert Molenberghs Biostatistics in a post-pandemic era: lessons learned for research, public health, drug and vaccine development, policy advice, and communication</b><br><br><b>Room: Effectenbeurszaal</b> |   |   |   |
| 10:30 – 11:00 | <b>Break</b>   |   |   |   |
| 11:00 – 12:30 | <b>Estimands for time-to-event outcomes: re-thinking old questions within the Estimand framework</b>   | <b>Biomarkers ESIG: Advancing Biomarker Insights in Precision Medicine and Digital Health</b>             | <b>Patient Focused Drug Development (PFDD) SIG: Hot Topics</b>                              | <b>Project Leadership Interactive Workshop</b><br><br>This interactive workshop focuses on the skills needed to successfully plan and execute a project. Attendees will look at different scenarios during an example project and explore approaches such as:- Understanding scope, responsibilities and expectations – Communication and planning with other functional leads – Leading the team to deliver and monitoring progress- Building a relationship with customers or stakeholders – Mitigating risk and problem solving. |
|               | Looking back on our oncology estimand SIG working group journey<br><b>Evgeny Degtyarev &amp; Kaspar Rufibach</b>   | Machine Learning as an enabler of precision medicine<br><b>Nils Ternès (Sanofi), Karl Köchert (Bayer)</b> | Introduction of the new PFDD SIG<br><b>Rachael Lawrance</b>                                 |   |
|               | Re-Thinking treatment effect measure in clinical trials with time-to-event outcomes and competing risks<br><b>Tobias Mütze &amp; Stefan Englert</b>  |   | Setting meaningful PRO objectives in oncology clinical trials<br><b>Konstantina Skaltsa</b> |   |
|               | Outcome and learnings from a recent survey on current practice in covariate adjustment and stratified analysis   | Digital biomarkers: the essential guide for statisticians.<br><b>Marzia A. Scelsi (Roche)</b>             | Emerging Patient-Centric Tolerability Endpoints<br><b>John Devin Peipert</b>                |   |

|               |  |   |   |   |
|---------------|--|---|---|---|
|               | Sarwar I. Mozumder   |   |   |   |
|               | Can we improve the analysis of safety events of special interest using the Estimand Framework?<br>Pedro Lopez-Romero | Panel discussion<br>Julia Chernova  | Digital endpoints opportunities and challenges<br>Piper Fromy   |   |
| 12:30 – 13:30 | Lunch<br>(Career Young Networking Session)   |   |   |   |
| 13:30 – 15:00 | How to Generate Evidence from Real World Data  | Causal Inference & Estimand   | Basket trials and personalised medicine   | Coaching v Mentoring Interactive Workshop |
|               | TBC  | Targeted Maximum Likelihood Estimation; Do we have a free lunch?<br>Bob Murray                  | Adding baskets to an ongoing basket trial with information borrowing:<br>When do you benefit?<br>Libby Daniells |   |
|               |  |   | When should we borrow across disease populations in a basket trial?<br>Elizabeth Pilling                        |   |
|               |  | Estimand in Formulation Studies: Insight from IMscin trials<br>Mahesh Shivhare, Matthias Meller | Clustering methods for frequentist adaptive basket trials<br>Michaela Maria Freitag                             |   |

|               |   |  |  |   |
|---------------|---|--|--|---|
|               |   | Estimand and Complex Innovative Designs<br><b>Olivier Collignon</b>  | Heterogeneity in treatment effects: random or real?<br><b>Thomas Jaki</b>  | Xinyi Zhu, Alun Bedding, Lucy Rowell  |
|               |   | Addressing Administrative Withdrawals in Clinical Trials in Estimation under the Treatment Policy Strategy<br><b>Yongming Qu</b> |  |   |
| 15:00 – 15:15 | Changeover  |  |  |   |
| 15:15 – 16:30 | Career Young Session 2  | Data Visualization and animation   | HTA  | Interactive session on Data Monitoring Committees   |
|               | Enhancing Variable Importance Interpretation in Machine Learning with Conditional Permutation Importance<br><b>Denis Engemann</b>                   | How To Draw A Really Bad Graph<br><b>Chris Harbron</b>   | Enhanced subgroup identification in heterogeneous clinical courses of disease burden using a machine learning score from CT images.<br><b>Grace Hyun Kim</b> | While DMCs are widely used considerable variability exists in conduct. This interactive session will focus on three topics: open sessions and open reports; communication pathways within and between the various parties involved with DMCs (i.e. the DMC themselves, the sponsor or academic clinical trials unit, and the independent statistical reporting group/CRO); and non-standard DMCs (e.g. adaptive designs). |
|               | Patterns of repeat non-fatal events and death in heart failure trials: implications for improving future research.<br><b>Audinga-Dea Hazewinkel</b> | Statistics - made accessible<br><b>Ursula Becker</b>   | Developing Trial-Based Risk Prediction Models: At the Intersection of Clinical Opinion and Data-driven Insights<br><b>Milana Ivkovic, Martin Bøg</b>         |   |
|               | R(ise) & Shiny: Taking steps to utilise R packages in Shiny applications<br><b>Emily Foreman</b>  | Data story telling<br><b>Bodo Kirsch</b>   | Open-source workflows for HTA: insights and implications from a pharma industry survey   |   |

|               |   |  |  |  |
|---------------|---|--|--|--|
|               | Recruitment-informed Bayesian<br>Analysis of Vaccine Efficacy<br><b>Marco Ratta</b> |  | Rossella Belleli (Roche), Amelie<br>Elsäßer (Boehringer Ingelheim),<br>Nermina Ferizovic (University<br>College London), Anders Gorst-<br>Rasmussen (Novo Nordisk) |  |
|               |   |  | QTwIST and shout: Censoring and<br>choice of Tau in Quality Adjusted<br>Time Without Symptoms of Toxicity.<br><b>Saiful Islam</b>                                  |  |
| 16:30 – 17:00 | Break   |  |  |  |
| 17:00 – 18:00 | Po: Gone in 60 seconds: 1 Minute Poster Previews                                    |  |  |  |
| 18:00 – 19:00 | Poster Session  |  |  |  |
| 19:00 – 20:00 | Free Time   |  |  |  |
| 20:00 – 22:00 | Social Event  |  |  |  |